​

GSK (GSK) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

GSK Stock Forecast

GSK (GSK) stock forecast, based on 27 Wall Street analysts, predicts a 12-month average price target of $58.00, with a high of $85.00 and a low of $36.00. This represents a 63.98% increase from the last price of $35.37.

$30 $41 $52 $63 $74 $85 High: $85 Avg: $58 Low: $36 Last Closed Price: $35.37

GSK Stock Rating

GSK stock's rating consensus is Hold, based on 27 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 9 Buy (33.33%), 16 Hold (59.26%), 2 Sell (7.41%), and 0 Strong Sell (0.00%).

Hold
Total 27 0 2 16 9 Strong Sell Sell Hold Buy Strong Buy

GSK Price Target Upside V Benchmarks

TypeNameUpside
StockGSK63.98%
SectorHealthcare Stocks 33.91%
IndustryDrug Manufacturers - General Stocks37.84%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$53.00
Last Closing Price$35.37$35.37$35.37
Upside/Downside--49.84%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25123118
Mar, 25123118
Feb, 25123-17
Jan, 25123-17
Dec, 24123-17
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jul 02, 2024Peter WelfordJefferies$53.00$38.3838.09%49.84%
Apr 11, 2024Vamil DivanGuggenheim$36.00$40.69-11.53%1.78%
Apr 11, 2024Mark PurcellMorgan Stanley$85.00$40.69108.90%140.32%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Nov 15, 2024Deutsche BankHolddowngrade
Oct 31, 2024GuggenheimBuyNeutraldowngrade
Oct 07, 2024JefferiesBuyBuyhold
Oct 01, 2024BarclaysEqual-WeightEqual-Weighthold
Aug 12, 2024JefferiesBuyBuyhold
Jul 22, 2024Morgan StanleyEqual-WeightEqual-Weighthold
Jul 11, 2024GuggenheimBuyBuyhold
Jul 08, 2024UBSNeutraldowngrade
Jul 02, 2024JefferiesBuyBuyhold
Jun 04, 2024JefferiesBuyBuyhold

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$2.89$2.19$2.41$1.20-----
Avg Forecast$2.33$2.23$2.68$3.04$3.07$3.25$3.65$3.98$4.06
High Forecast$2.39$2.28$2.76$3.11$3.23$3.37$4.12$4.19$4.21
Low Forecast$2.28$2.18$2.59$2.91$2.93$3.12$1.99$3.73$3.91
Surprise %24.03%-1.79%-10.07%-60.53%-----

Revenue Forecast

$25B $30B $35B $40B $45B $50B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$34.10B$34.11B$29.32B$30.33B-----
Avg Forecast$46.37B$46.08B$35.57B$37.78B$38.70B$40.25B$42.50B$44.48B$45.07B
High Forecast$47.21B$46.92B$36.42B$38.12B$39.69B$40.92B$43.74B$45.77B$46.39B
Low Forecast$45.59B$45.31B$34.63B$37.42B$37.19B$38.96B$41.25B$43.17B$43.75B
Surprise %-26.46%-25.98%-17.55%-19.72%-----

Net Income Forecast

$0 $4B $8B $12B $16B $20B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$5.75B$4.38B$4.92B$4.93B-----
Avg Forecast$9.59B$9.15B$11.01B$12.36B$12.66B$13.33B$12.56B$16.26B$16.69B
High Forecast$9.82B$9.37B$11.35B$12.78B$13.28B$13.84B$16.93B$17.21B$17.32B
Low Forecast$9.38B$8.95B$10.63B$11.95B$12.05B$12.82B$8.20B$15.32B$16.06B
Surprise %-40.06%-52.08%-55.31%-60.14%-----

GSK Forecast FAQ

Is GSK stock a buy?

GSK stock has a consensus rating of Hold, based on 27 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 9 Buy, 16 Hold, 2 Sell, and 0 Strong Sell, reflecting a consensus that GSK is a neutral investment for most analysts.

What is GSK's price target?

GSK's price target, set by 27 Wall Street analysts, averages $58 over the next 12 months. The price target range spans from $36 at the low end to $85 at the high end, suggesting a potential 63.98% change from the previous closing price of $35.37.

How does GSK stock forecast compare to its benchmarks?

GSK's stock forecast shows a 63.98% upside, outperforming the average forecast for the healthcare stocks sector (33.91%) and outperforming the drug manufacturers - general stocks industry (37.84%).

What is the breakdown of analyst ratings for GSK over the past three months?

  • April 2025: 12.50% Strong Buy, 25.00% Buy, 37.50% Hold, 12.50% Sell, 12.50% Strong Sell.
  • March 2025: 12.50% Strong Buy, 25.00% Buy, 37.50% Hold, 12.50% Sell, 12.50% Strong Sell.
  • February 2025: 14.29% Strong Buy, 28.57% Buy, 42.86% Hold, 0% Sell, 14.29% Strong Sell.

What is GSK’s EPS forecast?

GSK's average annual EPS forecast for its fiscal year ending in December 2024 is $3.07, marking a 155.83% increase from the reported $1.2 in 2023. Estimates for the following years are $3.25 in 2025, $3.65 in 2026, $3.98 in 2027, and $4.06 in 2028.

What is GSK’s revenue forecast?

GSK's average annual revenue forecast for its fiscal year ending in December 2024 is $38.7B, reflecting a 27.59% increase from the reported $30.33B in 2023. The forecast for 2025 is $40.25B, followed by $42.5B for 2026, $44.48B for 2027, and $45.07B for 2028.

What is GSK’s net income forecast?

GSK's net income forecast for the fiscal year ending in December 2024 stands at $12.66B, representing an 156.98% increase from the reported $4.93B in 2023. Projections indicate $13.33B in 2025, $12.56B in 2026, $16.26B in 2027, and $16.69B in 2028.